Evaxion A/S (EVAX)
| Market Cap | 25.02M -46.8% |
| Revenue (ttm) | 7.49M +135.9% |
| Net Income | -8.66M |
| EPS | -1.09 |
| Shares Out | 8.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 184,241 |
| Open | 2.770 |
| Previous Close | 2.760 |
| Day's Range | 2.710 - 3.210 |
| 52-Week Range | 2.710 - 6.920 |
| Beta | 0.56 |
| Analysts | Strong Buy |
| Price Target | 12.25 (+308.33%) |
| Earnings Date | Nov 19, 2026 |
About EVAX
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin... [Read more]
Financial Performance
In 2025, Evaxion's revenue was $7.53 million, an increase of 125.12% compared to the previous year's $3.34 million. Losses were -$7.71 million, -27.07% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for EVAX stock is "Strong Buy." The 12-month stock price target is $12.25, which is an increase of 308.33% from the latest price.
News
Evaxion Biotech announces biomarker data from Phase 2 EVX-01 trial
Evaxion announces new biomarker data from its phase 2 trial with personalized cancer vaccine EVX-01 in patients with advanced melanoma. The data demonstrate potent EVX-01 induced immune responses and ...
New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01
COPENHAGEN, Denmark, November 6, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces...
Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting
The data further validate the potential of EVX-04 as an off-the-shelf therapeutic vaccine for acute myeloid leukemia Data will be presented in a poster session at the American Society of Hematology (A...
Evaxion to present broad biomarker data from phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting
New data from the phase 2 trial with EVX-01 to be presented in both an oral and poster session COPENHAGEN, Denmark, November 3, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio ...
Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution
COPENHAGEN, Denmark, October 30, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, is proud ...
Evaxion Transcript: Study update
Phase II EVX-01 plus pembrolizumab produced a 75% ORR in advanced melanoma, with durable responses and sustained vaccine-induced T-cell activity. Results are encouraging but based on a small study.
Evaxion Slides: Study update
Evaxion has posted slides in relation to its latest quarterly earnings report, which was published on October 29, 2026.
Evaxion Biotech presents three-year immune and clinical outcome data for EVX-01
Evaxion announced new three-year immune and clinical outcome data for personalized cancer vaccine EVX-01 in patients with advanced melanoma. The data demonstrates EVX-01 inducing an immune response in...
Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
COPENHAGEN, Denmark, October 23, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces...
Evaxion Slides: Corporate presentation
Evaxion has posted slides in relation to its latest quarterly earnings report, which was published on October 21, 2026.
Evaxion Biotech reports three-year clinical outcome data for EVX-01
Evaxion announced new three-year clinical outcome data for personalized cancer vaccine EVX-01 in patients with advanced melanoma. All patients at three-year follow-up in the phase 2 trial maintained t...
Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
COPENHAGEN, Denmark, October 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces...
Evaxion Biotech to present new immune data on EVX-01 at SITC 2026
Evaxion will present new immune data for AI-designed personalized cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer, SITC, 2026 Annual Meeting, taking place in Phoenix, Arizona, Novembe...
Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting
COPENHAGEN, Denmark, October 2, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, will prese...
Evaxion applies its AI-Immunology™ platform in autoimmune diseases
Autoimmune diseases are characterized by high unmet medical need with most current treatments only addressing symptoms. Evaxion will apply AI-Immunology™ to target underlying pathologies The unique ca...
Evaxion Earnings Call Transcript: Q2 2026
Q2 2026 saw strong progress in oncology and infectious disease vaccine programs, with EVX-01 showing durable responses and new off-the-shelf vaccines advancing. Financials were in line with expectations, maintaining a cash runway into H2 2027, and partnership discussions remain active.
Evaxion Earnings release: Q2 2026
Evaxion released its Q2 2026 earnings on August 20, 2026, summarizing the period's financial results.
Evaxion Slides: Q2 2026
Evaxion has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 20, 2026.
Evaxion announces business update and second quarter 2026 financial results
COPENHAGEN, Denmark, August 20, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business...
Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program
COPENHAGEN, Denmark, August 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, expands it pipeli...
Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026
COPENHAGEN, Denmark, August 14, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a bu...
Merck discloses 1.21M share holding in Evaxion Biotech
In a regulatory filing after the close on Friday, Merck (MRK) disclosed that it holds 1,214,126 shares of Evaxion Biotech (EVAX). Evaxion shares are up 7c, or 2% to $3.17…
Evaxion Biotech to present EVX-01 clinical efficacy data at ESMO
Evaxion will present three-year clinical efficacy data from its phase 2 trial with personalized cancer vaccine candidate EVX-01 at the European Society for Medical Oncology, or ESMO, Congress 2026 to…
Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026
COPENHAGEN, Denmark, July 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will present three-...
Evaxion Biotech presents new data on EVX-V1
Evaxion A/S presents new data further supporting the multi-component concept of its cytomegalovirus vaccine program EVX-V1. Data is presented in a poster session at the International Herpesvirus Works...